Pitcairn Co. Raises Stock Holdings in Enovis Co. (NYSE:ENOV)

Pitcairn Co. boosted its holdings in shares of Enovis Co. (NYSE:ENOV) by 46.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 11,673 shares of the company’s stock after acquiring an additional 3,690 shares during the quarter. Pitcairn Co.’s holdings in Enovis were worth $512,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Amalgamated Bank raised its position in Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock valued at $1,136,000 after purchasing an additional 264 shares in the last quarter. Pinnacle Bancorp Inc. increased its stake in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after buying an additional 300 shares during the period. Arizona State Retirement System raised its holdings in shares of Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock valued at $711,000 after acquiring an additional 414 shares in the last quarter. UMB Bank n.a. lifted its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the period. Finally, New York State Teachers Retirement System grew its holdings in Enovis by 3.5% during the 4th quarter. New York State Teachers Retirement System now owns 13,538 shares of the company’s stock worth $594,000 after acquiring an additional 457 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Enovis in a research note on Wednesday.

Enovis Trading Down 3.8 %

NYSE ENOV opened at $32.52 on Friday. The stock has a market cap of $1.85 billion, a P/E ratio of -14.85 and a beta of 1.86. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $31.00 and a 12-month high of $62.79. The company has a fifty day simple moving average of $40.90 and a two-hundred day simple moving average of $43.09.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.